Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Instagram Outage Disrupts Thousands of U.S. Users 
SAN DIEGO, April 24, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that it will host a virtual Research & Development Day for analysts, investors and media on Tuesday, May 2, 2017, beginning at 9:00 a.m. PT. This event will be available via webcast and conference call.
The event will provide a comprehensive overview of Vical’s product pipeline with an emphasis on the HSV-2 and invasive aspergillosis programs, including presentations by members of the Vical leadership team and two leading experts:
- Anna Wald, MD, MPH, Professor, Department of Medicine, Epidemiology and Laboratory Medicine at the University of Washington and Lead Investigator in the ongoing Phase 2 trial of Vical’s HSV-2 therapeutic vaccine candidate
- Haran Schlamm, MD, infectious disease specialist and former Senior Medical Director at Pfizer, responsible for clinical development, medical and regulatory affairs for Pfizer’s antifungal portfolio
Listeners may access the accompanying slide presentation through the webcast at www.vical.com. The call and webcast are open on a listen-only basis to any interested parties. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 325-2239 (preferred), or (888) 455-2308 (toll-free), and reference confirmation code 9084195. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 9084195. The call also will be available live and archived through the events page at www.vical.com. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by e-mail at [email protected].
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Contact: Tony Ramos (858) 646-1127 Website: www.vical.com
